BioSpace News Archive

Akari Therapeutics, Plc today announced the appointment of industry veteran Wa’el Hashad to the Akari Board of Directors as an independent director.

Oryzon Genomics, S.A. today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BPD).

Daré Bioscience, Inc. today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN), and announced that Organon will pay Daré $1.0 million in July 2023.

CoImmune, Inc. today announced the publication of preclinical data demonstrating that a strategy based on the company’s proprietary Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell platform provides advantages over single-targeting CARs including improved efficacy and high specificity in a model of acute myeloid leukemia (AML).

Biocytogen Pharmaceuticals today announces an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that MEI Pharma shareholders vote “FOR” the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2023 before the market opens on Wednesday, July 26, 2023, and will hold a conference call on the same day at 8:30 a.m. EDT.

enVVeno Medical Corporation today provided an update ongoing SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) U.S. pivotal study for the VenoValve and announced two upcoming investor events (details below).

Oncoinvent AS today announced the appointment of Anders Månsson as Chief Executive Officer (CEO), effective September 1st , 2023.

Guardant Health announces reimbursement approval of Guardant360 ® CDx liquid biopsy test in Japan.